Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.70 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.70 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.70 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168083 | 0.94 | CACNA1I (0.75) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL3827189 | 0.94 | CACNA1I (0.75) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL3516193 | 0.94 | CACNA1I (0.75) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL3515933 | 0.91 | CACNA1I (0.79) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL8245108 | 0.91 | CACNA1I (0.79) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL8247891 | 0.91 | CACNA1I (0.85) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL3517665 | 0.91 | CACNA1I (0.70) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL3830482 | 0.91 | CACNA1I (0.70) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL8249420 | 0.90 | CACNA1I (0.69) | CACNA1IKCNH2CACNA1GCHRM2HRH1 | |
| SCHEMBL3516275 | 0.90 | CACNA1I (0.69) | CACNA1IKCNH2CACNA1GCHRM2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222387-A1 | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-09-02 | — | — | US | claimed |
| EP-1896414-A4 | 3-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1896414-A2 | 3-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2007002361-A2 | 3-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20100222387-A1 | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-09-02 | — | — | US | disclosed |
| US-20100222387-A1 | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-09-02 | — | — | US | disclosed |
| US-20100222387-A1 | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-09-02 | — | — | US | disclosed |
| WO-2007002361-A2 | 3-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222387-A1 | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | CACNA1I 2/4885KCNH2 35/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.